You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

rituximab-refractory

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)

Not yet recruiting
  • CNS Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 22, 2023

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

Not yet recruiting
  • Large B-cell Lymphoma
  • B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Lymphoma Trial in Houston (Rituximab, Lenalidomide, Valemetostat)

Not yet recruiting
  • Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jan 4, 2023

Follicular Lymphoma Trial in Shanghai (lenalidomide, rituximab, parsaclisib)

Not yet recruiting
  • Follicular Lymphoma
  • Shanghai, Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
May 10, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide,

Recruiting
  • Follicular Lymphoma and Marginal Zone Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
  • lenalinomide
  • Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Feb 13, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Pharmacological Action Trial (Rituximab, Dexamethasone)

Not yet recruiting
  • Pharmacological Action
  • (no location specified)
Sep 22, 2022

Refractory Myasthenia Gravis, Rituximab Trial in Guangzhou (Rituximab)

Recruiting
  • Refractory Myasthenia Gravis
  • Rituximab
  • Guangzhou, China
    First Affiliated Hospital, Sun Yat-Sen University
Apr 26, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

NonHodgkin's Lymphoma Refractory Trial in El Segundo (N803, CD19t-haNK suspension, Cyclophosphamide)

Not yet recruiting
  • NonHodgkin's Lymphoma Refractory
  • El Segundo, California
    CSSIFM
Nov 9, 2022

Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome
  • +2 more
  • Wuhan, Hubei, China
    Department of Hematology Tongji Hospital, Tongji Medical College
Oct 7, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Guangzhou, Guangdong, China
  • +10 more
Oct 8, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +5 more
  • (no location specified)
Jul 21, 2023